|VENTURE FUNDING TOTAL||$9.35M|
|Venture Round, 8/09 |
Hudson Capital Management
Antigenics, Inc., a biotechnology company, develops treatments for cancers and infectious diseases. It offers Oncophage, a personalized therapeutic cancer vaccine candidate, which is in Phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. The companyâ€™s products also include Aroplatin, a liposomal chemotherapeutic, which is in Phase I clinical trial for the treatment of solid tumors and non-Hodgkinâ€™s lymphoma; AG-707, a therapeutic vaccine program that is in Phase I clinical trial for the treatment of genital herpes; and QS-21, an adjuvant used in various vaccines, including hepatitis, lyme diseases, human immunodeficiency virus, influenza, cancer, Alzheimerâ€™s disease, and malaria. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York, New York.